Conestoga Capital Advisors LLC Has $1.48 Million Position in Alpha Teknova, Inc. (NASDAQ:TKNO)

Conestoga Capital Advisors LLC cut its holdings in shares of Alpha Teknova, Inc. (NASDAQ:TKNO) by 32.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 305,129 shares of the company’s stock after selling 148,770 shares during the period. Conestoga Capital Advisors LLC’s holdings in Alpha Teknova were worth $1,477,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TKNO. Roubaix Capital LLC acquired a new position in shares of Alpha Teknova during the third quarter worth $2,015,000. FourWorld Capital Management LLC bought a new position in Alpha Teknova during the 1st quarter worth $135,000. State Board of Administration of Florida Retirement System acquired a new position in Alpha Teknova during the 1st quarter worth about $35,000. Finally, Redmile Group LLC raised its position in shares of Alpha Teknova by 6.5% during the first quarter. Redmile Group LLC now owns 171,453 shares of the company’s stock worth $434,000 after acquiring an additional 10,448 shares during the last quarter. 13.81% of the stock is owned by institutional investors.

Alpha Teknova Trading Up 6.6 %

TKNO traded up $0.45 during trading on Friday, reaching $7.25. 38,176 shares of the stock traded hands, compared to its average volume of 222,806. The stock’s 50-day moving average is $5.28 and its 200 day moving average is $3.31. Alpha Teknova, Inc. has a 12 month low of $1.15 and a 12 month high of $7.49. The company has a quick ratio of 3.28, a current ratio of 4.76 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $386.43 million, a PE ratio of -7.68 and a beta of 0.43.

Alpha Teknova (NASDAQ:TKNO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $9.61 million during the quarter, compared to the consensus estimate of $9.50 million. Alpha Teknova had a negative return on equity of 37.00% and a negative net margin of 98.08%. During the same period in the previous year, the company posted ($0.25) earnings per share. Equities analysts anticipate that Alpha Teknova, Inc. will post -0.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “overweight” rating and issued a $5.00 target price on shares of Alpha Teknova in a report on Wednesday, July 10th.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.